Millrace Asset Group Inc. Buys New Stake in Health Catalyst, Inc. (NASDAQ:HCAT)

Millrace Asset Group Inc. bought a new stake in Health Catalyst, Inc. (NASDAQ:HCAT - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 192,616 shares of the company's stock, valued at approximately $1,568,000. Health Catalyst makes up 1.6% of Millrace Asset Group Inc.'s portfolio, making the stock its 28th biggest holding. Millrace Asset Group Inc. owned about 0.32% of Health Catalyst as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the company. Quest Partners LLC acquired a new position in Health Catalyst during the third quarter worth about $34,000. Nisa Investment Advisors LLC boosted its holdings in shares of Health Catalyst by 461.0% during the 2nd quarter. Nisa Investment Advisors LLC now owns 6,367 shares of the company's stock worth $41,000 after purchasing an additional 5,232 shares during the last quarter. Quarry LP grew its position in shares of Health Catalyst by 59.4% in the second quarter. Quarry LP now owns 7,002 shares of the company's stock valued at $45,000 after purchasing an additional 2,610 shares in the last quarter. nVerses Capital LLC acquired a new stake in shares of Health Catalyst in the third quarter valued at approximately $59,000. Finally, Perfromance Wealth Partners LLC acquired a new stake in shares of Health Catalyst in the second quarter valued at approximately $64,000. 85.00% of the stock is owned by institutional investors and hedge funds.

Health Catalyst Trading Down 0.2 %

NASDAQ:HCAT traded down $0.02 during trading hours on Tuesday, reaching $8.50. 433,620 shares of the stock were exchanged, compared to its average volume of 560,789. Health Catalyst, Inc. has a twelve month low of $5.42 and a twelve month high of $11.41. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32. The business has a 50-day moving average of $8.13 and a two-hundred day moving average of $7.28. The company has a market capitalization of $517.23 million, a price-to-earnings ratio of -6.34 and a beta of 1.32.

Health Catalyst (NASDAQ:HCAT - Get Free Report) last released its earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). The firm had revenue of $76.40 million during the quarter, compared to analyst estimates of $76.27 million. Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The business's revenue was up 3.5% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.22) earnings per share. On average, equities analysts predict that Health Catalyst, Inc. will post -0.35 EPS for the current year.

Insider Buying and Selling

In related news, COO Daniel Lesueur sold 8,137 shares of the business's stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $7.58, for a total transaction of $61,678.46. Following the completion of the transaction, the chief operating officer now directly owns 140,108 shares of the company's stock, valued at $1,062,018.64. The trade was a 5.49 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Kevin Lee Freeman sold 7,500 shares of the stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total value of $54,150.00. Following the completion of the sale, the insider now directly owns 255,881 shares in the company, valued at $1,847,460.82. This represents a 2.85 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 34,068 shares of company stock valued at $257,555 in the last ninety days. Company insiders own 2.50% of the company's stock.

Analysts Set New Price Targets

Several analysts have issued reports on HCAT shares. JPMorgan Chase & Co. upped their target price on Health Catalyst from $10.00 to $13.00 and gave the company an "overweight" rating in a report on Wednesday, September 4th. Royal Bank of Canada upped their price objective on shares of Health Catalyst from $8.00 to $9.00 and gave the company a "sector perform" rating in a report on Thursday, November 7th. Citigroup lifted their target price on shares of Health Catalyst from $9.00 to $10.50 and gave the stock a "buy" rating in a research note on Wednesday, November 13th. Cantor Fitzgerald reissued an "overweight" rating and issued a $16.00 price target on shares of Health Catalyst in a research note on Friday, October 4th. Finally, Stephens raised their price target on shares of Health Catalyst from $7.00 to $9.00 and gave the stock an "equal weight" rating in a report on Thursday, November 14th. Three equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $11.79.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.